false 0000718937 0000718937 2020-09-14 2020-09-14









Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of report (Date of earliest event reported): September 14, 2020



STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)




25651 Atlantic Ocean Drive

Lake Forest, California



(Address of Principal Executive Offices)


(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered




Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01 Entry into a Material Definitive Agreement.


On September 14, 2020, STAAR Surgical Company (the “Company”) entered into a Lease Agreement (the “Lease”) with Calderari & Schwab (“Lessor”), to expand its footprint of leased real property located at Hauptstrasse 104, 2560 Nidau, Switzerland, including additional portions of a commercial building for a total of approximately 2,396 square meters (the “Premises”). The Lease begins on April 1, 2021 and has an initial term of ten years. The additional leased space is intended to accommodate expanded operations, including increased capacity for production and sales support. The Company has an option to extend the Lease for a period of five years.

The foregoing summary is qualified in its entirety by reference to the Lease, a translated version of which is filed as Exhibit 10.39 to this Current Report on Form 8-K and incorporated herein by this reference.


Item 7.01 Regulation FD Disclosure.


On September 14, 2020, the Company published a press release announcing that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its U.S. FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens.” A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.


The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.



Item 9.01 Financial Statements and Exhibits


Exhibit No.








Lease Agreement by and between the Company and Calderari & Schwab.


Press release of the Company dated September 14, 2020.







Cover Page Interactive Data File (embedded within the Inline XBRL document).








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


STAAR Surgical Company 


September 14, 2020


/s/ Caren Mason



Caren Mason



President and Chief Executive Officer